Conference Coverage

Vemurafenib After Ipilimumab Linked to Rash


 

AT THE ANNUAL MEETING OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY

Dr. Harding disclosed no relevant conflicts of interest. Dr. Sznol disclosed that he is a consultant to Abbott Laboratories, Anaeropharma, BioVex, Bristol-Myers Squibb, Genesis Biopharma, Genzyme, and Prometheus; receives honoraria from Prometheus; and receives research funding from Bristol-Myers Squibb.

Pages

Recommended Reading

Labs Find Evidence of Cancer Stem Cells
MDedge Dermatology
Isotretinoin Quells EGFR Inhibitor-Related Rash
MDedge Dermatology
Blood Pressure Meds Linked to Lip Cancer
MDedge Dermatology
Let Lip Defect Size Drive Treatment
MDedge Dermatology
A Musical Marketing Plan: The Skinny Podcast
MDedge Dermatology
Melanoma Sinks Hook Into Coral Reef Trout
MDedge Dermatology
KIT Inhibition Promising for Select Few
MDedge Dermatology
Skin Cancer Drug Steps Into New Alzheimer's Study
MDedge Dermatology
Kaposi's Sarcoma Makes Unwelcome Return
MDedge Dermatology
Photoprotection for Preventing Skin Cancer and Premature Skin Aging
MDedge Dermatology